NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed 'INVO Fertility, Inc.'
In connection with the planned separation, the Company has been renamed to 'INVO Fertility, Inc.' effective Monday, April 14, 2025, and its Nasdaq ticker symbol will be changed to 'IVF' as soon as practicable. The Company will provide additional information on the expected date for the new symbol to go effective.
With this separation, the Company returns to its previous, exclusive focus on the fertility marketplace – the establishment, acquisition and operation of new fertility clinics and the distribution of the Company's FDA-cleared INVOcell device.
The Company plans to divest a majority stake in its wholly owned subsidiary, NAYA Therapeutics Inc. ('NAYA TX'). Through the retention of a minority position, the Company seeks to benefit from the potential value appreciation that could be generated from the clinical development of NAYA TX's bifunctional antibodies. This revised corporate structure aims to enable both businesses to focus on their respective opportunities and operations, with the existing management team and board of directors set to lead the Company. NAYA TX will return to being a privately held biotechnology company led by its management team and board. The final separation is subject to completing definitive transaction documents and key closing conditions, including receipt of necessary approvals.
'Moving forward, we will leverage our existing, revenue-generating fertility operations with operating centers in Wisconsin, Alabama, and Georgia, to acquire and build new centers across the U.S.,' stated Steve Shum, CEO of INVO Fertility. 'We believe the fertility market opportunity remains large and growing, as confirmed by the U.S. President's recent executive order aimed at reducing the cost of IVF and expanding access to fertility services.'
'We remain enthusiastic about NAYA TX's assets and their significant potential upside, which we hope to monetize in the future through value appreciation in the minority stake we plan to retain. At the same time, the return of the two businesses to independent entities is expected to enable a more focused effort with dedicated teams. We believe the respective shareholders for each business agree and support this revised structure and approach.'
The Company previously filed an extension for the filing of its Annual Report on Form 10-K for the year ended December 31, 2024. The Company is in the process of completing its financial statements and other disclosures for the fiscal year ended December 31, 2024.
About INVO Fertility, Inc.
We are a healthcare services fertility company dedicated to expanding assisted reproductive technology ('ART') care to patients in need. Our principal commercial strategy is focused on building, acquiring and operating fertility clinics, including 'INVO Centers' dedicated primarily to offering the intravaginal culture ('IVC') procedure enabled by our INVOcell® medical device ('INVOcell') and US-based, profitable in vitro fertilization ('IVF') clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of our INVOcell technology solution into third-party owned and operated fertility clinics. The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more natural, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination ('IUI'). For more information, please visit www.invobio.com.
About NAYA Therapeutics, Inc.
NAYA Therapeutics is a clinical-stage biopharmaceutical company dedicated to advancing oncology outcomes through the development of next-generation bifunctional antibodies. Its portfolio currently includes NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of HCC with a unique mechanism of action targeting non-responders to the current immunotherapy standard of care (70-85% of the current treatable market), cleared to enroll patients in a Phase I/IIa monotherapy trial in H2 2025, NY-500, an AI-optimized PD-1 x VEGF bifunctional antibody aiming to be the first PD-1 x VEGF to market in HCC, with translational clinical and preclinical data in 2025 and Phase I/II in HCC to be initiated in early 2026, and NY-338, a CD38 x NKp46 bifunctional antibody for the treatment of multiple myeloma with a unique mechanism of action enhancing safety & efficacy and a differentiated profile to daratumumab and T-Cell engagers, aiming to enroll patients in its Phase I/II clinical trials in early 2026. For more information, please visit www.nayatx.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact:
INVO Fertility, Inc. Steve Shum, CEO 978-878-9505sshum@invobio.com
NAYA Therapeutics, Inc. Lyn Falconio, Chief Communications Officer917-575-1844lyn@nayatx.com
Investor Contact Lytham Partners, LLC Robert Blum 602-889-9700 INVO@lythampartners.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Analog Devices Shares Jump After Blowout Quarter and Upbeat Forecast
This article first appeared on GuruFocus. Aug 20 - Analog Devices (NASDAQ:ADI) gained roughly 4% on Wednesday after reporting fiscal third-quarter results that topped Wall Street expectations and offering stronger-than-expected guidance for the current quarter. The move came even as most other semiconductor stocks traded lower. Warning! GuruFocus has detected 11 Warning Signs with ADI. Revenue in the third quarter rose about 4% above consensus and exceeded the high end of the company's guided range. Communications and Consumer segments delivered notable strength, with sales beating analyst forecasts by 15% and 6%, respectively. Management projected fiscal fourth-quarter revenue to grow 4% sequentially, which is 6% ahead of consensus expectations. Analysts were quick to weigh in. Wells Fargo reiterated an Equal Weight rating with a $235 price target, noting solid bookings and pointing to forward visibility as a key factor for recovery heading into fiscal 2026. Evercore maintained its Outperform rating with a $280 price target, citing the revenue beats and robust demand outlook. Truist kept its Hold rating and $219 price target, highlighting that tariffs and trade fluctuations still cloud the broader market backdrop. With macro uncertainty continuing, investors seem buoyed by the fact that Analog Devices is able to move through the changing environment and still show a high level of demand in the most important markets.
Business Wire
12 minutes ago
- Business Wire
Deadline Alert: Charter Communications, Inc. (CHTR) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP reminds investors of the upcoming October 14, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Charter Communications, Inc. ('Charter' or the 'Company') (NASDAQ: CHTR) common stock between , inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR CHARTER INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On July 25, 2025, Charter released its second quarter 2025 financial results, reporting that total internet customers had declined by 117,000, compared to about 100,000 in the second quarter of 2024, when adjusted to remove the prior year's impact of Affordable Connectivity Program ("ACP") related disconnected. The Company's total video customers also decreased by 80,000. On this news, Charter's stock price fell $70.25, or 18.5%, to close at $309.75 per share on July 25, 2025, thereby injuring investors. What Is the Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the impact of the ACP end was a material event the Company was unable to manage or promptly move beyond; (2) the ACP end was actually having a sustaining impact on Internet customer declines and revenue; (3) neither was the Company executing broader operations in a way that would compensate for, or overcome the impact, of the ACP ending; (4) the Internet customer declines and broader failure of Charter's execution strategy created much greater risks on business plans and earnings growth than reported; (5) accordingly, the Company had no reasonable basis to state the Company was successfully executing operations, managing causes of Internet customer declines, or provide overly optimistic statements about the long term trajectory of the Company and EBITDA growth; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Charter common stock during the Class Period, you may move the Court no later than October 14, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us to Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq. Glancy Prongay & Murray LLP 1925 Century Park East, Suite 2100 Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
17 minutes ago
- Yahoo
UBS sees buy opportunity in Microsoft as pricing changes boost cloud revenues
-- UBS said in a note on Wednesday that Microsoft's latest pricing and licensing changes are likely to drive stronger cloud revenues, reinforcing its Buy rating on the stock. 'Last week, Microsoft (NASDAQ:MSFT) announced a new pricing and licensing model that partners described as 'significant' and 'very aggressive,' prompting us to explore the change in detail,' UBS analysts wrote. The bank said Microsoft is 'standardizing pricing across most of its customer tiers on EA contract types, with partners consistent in their feedback that this results in a net price increase.' The changes, effective Nov. 1, will apply to Microsoft's Online Services suite, including Azure, Microsoft 365/Office 365, and Dynamics 365. UBS estimated these products represent about 55% of revenues. Government and education contracts, as well as on-premise products, are exempt. According to partners cited by UBS, the net price increase ranges between '3-6% to 10-14%.' UBS stated that it assumes the new pricing was reflected in Microsoft's guidance and that the firm now has 'marginally more confidence in our outlook for total c/c revenue growth of 14% in FY26E.' Analysts cautioned, however, that the benefits may be gradual because the increases apply as contracts renew and do not cover Microsoft's largest global accounts. The bank also noted that 'partners flagged a series of separate pricing/licensing changes that Microsoft has been making on its on-prem suite that we conclude could have accelerated Azure migration activity of late.' UBS kept its $650 price target and Buy rating on MSFT unchanged, citing the company's strong positioning in artificial intelligence. 'We still view the stock as being reasonably priced given how levered Microsoft is to the AI phenomenon,' the analysts said. Related articles UBS sees buy opportunity in Microsoft as pricing changes boost cloud revenues Clients buying into summer rally, bracing for later pullback, says BofA's Hartnett After soaring 149%, this stock is back in our AI's favor - & already +25% in July
